Together, cancer meets its match
Omico is changing the way we fight cancer by accelerating access to precision oncology. We are a national, independent, not-for-profit organisation, uniting Australia’s world-class cancer institutes, researchers, clinicians, industry partners and government like never before. By leveraging a nationwide network of expertise and resources, we aim to improve outcomes for all Australian cancer patients. With fast-tracked molecular and genomic screening, biomarker-led trial set up and patient enrolment from the entire nation, we’re accelerating access to next generation treatments and preventive strategies.
What we do
We aim to improve outcomes for Australians living with cancers, by:
- Increasing access to genomic profiling to detect unique genetic variations in cancer patients’ tumours to identify potential matches to new targeted treatments options
- Growing and streamlining biomarker-led clinical trials by expediting patient recruitment and site setup, and attracting more international trials to Australia, facilitating faster transitions from discovery to clinical application
- Advancing a research-led model of care as to open new treatment pathways for patients, and supporting drug development and cancer research through the collection of real-world data
How our molecular screening works
If you or someone you know has advanced, incurable or an earlier diagnosis of a poor prognosis cancer or is at high-risk for cancer (due to hereditary conditions) then:
- Your doctor completes an online referral form
- You sign a consent form
- Omico assesses the genes and other molecules in your cancer tissue
- Our experts match results to an existing therapy or clinical trial of a new drug
- Process takes 8 to 10 weeks
Researchers
Meet intellectually-stimulating research that changes cancer care and transforms lives.
Clinicians
Meet accelerated access to innovative new therapies for your patients.
Government
Meet an opportunity to advance the nation’s health and wealth.
Advocacy Groups
Meet a partner that can help you make a real difference for those affected by cancer.
Who we work with
Recent news
Understanding Your Options in Cancer Care: Omico’s 2025 Genomics Education Events for Patients, Families, and Carers
Omico will take another key step forward in 2025 to educate those diagnosed with challenging cancers, their families and carers, on the significant technological advances and innovative treatment options now available through genomics.
ASPiRATION Study: Collaborative Efforts Drive Exceptional Patient Follow-Up Data in Advancing Lung Cancer Research
At Omico, collaboration and data-driven insights are core to our mission to advance cancer care. Through the ASPiRATION study*, we have partnered with the Thoracic Oncology Group of Australasia (TOGA), NHMRC Clinical Trials Centre (CTC), University of Sydney, and industry partners, supported by the Australian Government’s Medical Research Future Fund (MRFF) and Roche Products Pty. Limited. Together, we are exploring the impact of comprehensive genomic profiling (CGP) and precision medicine for metastatic lung cancer—a disease with a challenging five-year survival rate of only 17%.
Professor David Thomas Receives NSW Premier’s Award for Outstanding Cancer Researcher of 2024: Award Honours Lifetime Contributions to Cancer Research and Advancing Precision Oncology as Standard Care
Professor David Thomas, Founder of not-for-profit genomics organisation, Omico, and Director, Centre of Molecular Oncology, UNSW has been awarded NSW’s highest accolade for cancer research at the NSW Premier’s Awards for Outstanding Cancer Research.